611 related articles for article (PubMed ID: 27574733)
1. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system.
Das S; Shetty RK; Kumar A; Shridharan RN; Tatineni R; Chi G; Mukherjee A; Das S; Subbarao SM; Karande AA
PLoS One; 2013; 8(1):e53619. PubMed ID: 23341957
[TBL] [Abstract][Full Text] [Related]
4. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
[TBL] [Abstract][Full Text] [Related]
5. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
[TBL] [Abstract][Full Text] [Related]
7. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
8. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
mBio; 2017 May; 8(3):. PubMed ID: 28512091
[TBL] [Abstract][Full Text] [Related]
9. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
11. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
[TBL] [Abstract][Full Text] [Related]
13. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
[TBL] [Abstract][Full Text] [Related]
14. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
[TBL] [Abstract][Full Text] [Related]
17. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
[TBL] [Abstract][Full Text] [Related]
18. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
19. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
20. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
